Abstract: In some embodiments, a wound dressing that incorporates a number of sensors or sensors separate from the wound dressing can be utilized in order to monitor characteristics of a wound as it heals or to identify one or more risk factors or conditions that may precipitate a wound. In some implementations, a wound dressing configured to be positioned in contact with a wound includes a substantially flexible substrate supporting one or more sensors. The one or more sensors can include temperature sensors, conductivity sensors, multispectral optical measurements sensors, pH sensors, pressure sensors, colorimetric sensors, optical sensors, ultraviolet (UV) sensors, or infrared (IR) sensors.

Abstract: The present invention relates to a method for preparing dexmedetomidine having the following formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, comprising the following successive steps: a) asymmetric hydrogenation of a methylene derivative of the following formula (II): in order to obtain dexmedetomidine, and b) optionally salifying and/or solvating dexmedetomidine in order to obtain a pharmaceutically acceptable salt and/or solvate of dexmedetomidine, wherein the methylene derivative of formula (II) is prepared from a halide of the following formula (V), in which Hal2 represents a halogen atom such as Br, and a cyanoimidazole of the following formula (VI).

Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.

Abstract: Described herein is an absorbent article including (a) an absorbent core, a first nonwoven material, a second nonwoven material, and a bond area; and (b) a polymeric filler composition disposed within the bond area. The polymeric filler composition has less than 1% of a tackifier. The polymeric filler composition is chosen from a propylene butene copolymer, a polypropylene homopolymer, a propylene ethylene copolymer, and mixtures thereof. The polymeric filler composition has a Tensile Strength at Yield of from about 0.5 MPa to about 10 MPa. The bond area has a Peak Peel Strength of from about 0.1 N/cm to about 9 N/cm after exposure to a skin-protecting material for 24 hours.

Abstract: The present disclosure provides pyrimidine compounds useful as tyrosine kinase inhibitors, and particularly epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors. The disclosed EGFR inhibitors are effective against acquired resistance mutations appearing after treatment of existing EGFR inhibitors. The present disclosure also provides methods of treating cancer using pyrimidine compounds and pharmaceutical compositions comprising pyrimidine compounds. The methods of treating cancer may be directed to cancer with acquired resistance mutations.

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: Garments comprise one or more bonds formed within a joined region of the garment; a garment base comprising at least one interior base layer and at least one exterior base layer; and a moisture capture assembly joined to the garment base within at least the joined region. The moisture capture assembly comprises a moisture retention portion configured to absorb and retain moisture from the wearer and an anti-leak portion configured to restrict moisture from exiting the moisture retention portion.

Abstract: Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

Abstract: An apparatus to maintain an environment over an anterior surface of a patient eye can include an enclosure sized and shaped to be seated about the patient eye to form a cavity within the enclosure. The enclosure can be configured to contain a fluid other than ambient air in contact with the patient eye. The apparatus can include a fluid regulator in communication with the enclosure, where the fluid regulator can be configured to regulate the composition of the fluid contained within the enclosure.

Abstract: A device is provided for enclosing an extremity of a patient for container efficient wound cleaning and for integrating draping prior to surgery. A loose-fitting flexible container with a flexible seal is provided for enclosing the extremity and treating the extremity in a controlled fashion to reduce or eliminate spillage and unwanted dispersion of antiseptic solution. Sealed to the flexible container is a vacuum packed, folded and rolled sterile surgical drape. The combination of a flexible container and a sterile pre-positioned surgical drape in a single device provides the advantage of controlled decontamination of the skin or wound while simultaneously providing the advantage of pre-positioning a surgical drape. The use of the device also provides the advantages of reduced operating room fires and biohazard dispersion risk and reduced cost by reduction of total operating room time per procedure.

Abstract: Systems, methods, and apparatuses for irrigating a tissue site are described. The system can include a tissue interface and a sealing member configured to be placed over the tissue site to form a sealed space, and a negative-pressure source fluidly coupled to the sealed space. The system includes an irrigation valve having a housing, a piston disposed in the housing, a fluid inlet to fluidly couple a fluid inlet chamber to a fluid source, and a fluid outlet to fluidly couple a fluid outlet chamber to the sealed space. A piston passage extends through the piston and fluidly couples the fluid inlet chamber and the fluid outlet chamber, and a biasing member is coupled to the piston to bias the irrigation valve to a closed position. The negative-pressure source is configured to move the piston between the closed position and an open position to draw fluid to the sealed space.

Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

Abstract: The present disclosure provides a process for the preparation of Trifarotene. The disclosure also provides novel intermediates in the process described herein. Also provided are novel polymorphs of Trifarotene.

Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Abstract: Substituted benzoxazole and benzofuran chemical entities of Formula (I): wherein, V, W, X, Y, Z, and m have any of the values described herein and compositions comprising such chemical entities; processes for making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; and the treatment of one or more disorders, including neurological, cognitive, immunological, and inflammatory disorders, as well as other conditions and diseases involving PDE7 or cyclic nucleotide signaling.

Abstract: A cyclic compound formed by a Friedel-Crafts reaction at positions 1 and 3 of carbazole and a preparation method thereof are disclosed. The compound is formed by connecting an achiral type I di-(tertiary alcohol) synthon constructed from fluorenyl and benzene or a derivative thereof, at position 9 of fluorenyl with positions 1 and 3 of carbazole, forming a closed ring structure with a clear and durable shape, having clear side lengths and vertices on the nanometer scale.

Abstract: A system for managing female incontinence includes a body of biocompatible material configured to fit between the labia minora and the vestibule floor, the body having a surface configured to occlude the urethral meatus, a first adhesive layer disposed on at least a first portion of the surface and configured to provide a sealing engagement between the body and the urethral meatus, and a second adhesive layer disposed over the first adhesive layer and configured to provide a sealing engagement between the body and the urethral meatus, wherein the second adhesive layer is removable from the first adhesive layer.

Abstract: Absorbent laminates and multi-layer, folded absorbent cores comprising the absorbent laminates for use in absorbent articles are presented. Specifically, multi-layer, folded absorbent cores are presented that are formed from an absorbent laminate comprising an absorbent layer between two tissue layers, in which the absorbent core includes a central channel running longitudinally along the core and crenellations profiled along the thickness of the core and providing enhanced liquid distribution across the core surface area or profile and improved liquid absorption into the laminate.

Abstract: Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.